Multicenter Phase II Clinical Trial of Sorafenib Combined with Transarterial Chemoembolization for Advanced Stage Hepatocellular Carcinomas (Barcelona Clinic Liver Cancer Stage C): STAB Study
Subgroup analysis of the SHARP and Asia-Pacific trials showed a median overall survival of 5.6-9.7 months in advanced stage HCC with Sorafinib monotherapy. The present study demonstrates an overall survival of 17.3 months compared to these trials. However, it should be noted that SHARP and Asia-Pacific trials were much larger trials with a more advanced patient population and more advanced BCLC stage than the presented study. The authors attribute the improved survival to patient selection and exclusion of patients with first order portal vein thrombosis. Similar studies comparing overall survival for TACE plus Sorafinib versus TACE alone and Sofafinib alone have shown benefit of combination therapy (7-11 months vs 4.9-6.0 months vs 5.9 months). These findings are concordant to the results of this study and highlight the benefit of combination therapy in Child A population with BCLC C disease.
Associate Professor and Section Chief,
University of Texas Health Science Center